Navigation Links
What really prompts the dog's 'guilty look'
Date:6/11/2009

Amsterdam, 11 June 2009 - What dog owner has not come home to a broken vase or other valuable items and a guilty-looking dog slouching around the house? By ingeniously setting up conditions where the owner was misinformed as to whether their dog had really committed an offense, Alexandra Horowitz, Assistant Professor from Barnard College in New York, uncovered the origins of the "guilty look" in dogs in the recently published "Canine Behaviour and Cognition" Special Issue of Elsevier's Behavioural Processes (http://www.elsevier.com/locate/behavproc).

Horowitz was able to show that the human tendency to attribute a "guilty look" to a dog was not due to whether the dog was indeed guilty. Instead, people see 'guilt' in a dog's body language when they believe the dog has done something it shouldn't have even if the dog is in fact completely innocent of any offense.

During the study, owners were asked to leave the room after ordering their dogs not to eat a tasty treat. While the owner was away, Horowitz gave some of the dogs this forbidden treat before asking the owners back into the room. In some trials the owners were told that their dog had eaten the forbidden treat; in others, they were told their dog had behaved properly and left the treat alone. What the owners were told, however, often did not correlate with reality.

Whether the dogs' demeanor included elements of the "guilty look" had little to do with whether the dogs had actually eaten the forbidden treat or not. Dogs looked most "guilty" if they were admonished by their owners for eating the treat. In fact, dogs that had been obedient and had not eaten the treat, but were scolded by their (misinformed) owners, looked more "guilty" than those that had, in fact, eaten the treat. Thus the dog's guilty look is a response to the owner's behavior, and not necessarily indicative of any appreciation of its own misdeeds.'/>"/>

Contact: Ewa Kittel-Prejs
e.kittel-prejs@elsevier.com
44-778-631-3420
Elsevier
Source:Eurekalert

Page: 1 2

Related biology news :

1. Disordered amino acids may really be there to provide wiggle room for signaling protein
2. Is it really only our kidneys that control blood pressure?
3. What is really happening to the Greenland icecap?
4. For the birds or for me? Why do conservationists really help wildlife?
5. Hot peppers really do bring the heat
6. Early bird project really gets the worm
7. When is a stem cell not really a stem cell?
8. Lupus gene finding prompts call for more DNA samples
9. A recipe for dog bite injuries: Kids, dogs and warm weather
10. Big cats, wild pigs and short-eared dogs -- oh, my!
11. Pigs and dogs can bridge gap between mice and humans in developing new therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2015)... MINNETONKA, Minn. , Feb. 12, 2015 /PRNewswire/ ... technology company specializing in clinical study management systems, ... Partner Program , further distinguishing iMedNet ... for Clinical Research Organizations (CROs) and healthcare consultants.  ... sales support, prospective customer referrals and numerous co-marketing ...
(Date:2/10/2015)... 2015  Alere Inc. (NYSE: ALR), a global ... for the quarter ended December 31, 2014. ... of Alere said, "We made substantial progress in ... global leader in rapid diagnostics and delivering against ... divestiture in early January enabled us to substantially ...
(Date:2/5/2015)... , Feb. 5, 2015  Marken is starting ... company and has launched a new marketing campaign to ... Organization (CLO).  The new campaign focuses on First ... protocol and shipments. The first headline in ... aligns Marken,s priorities with its client,s priorities. Marken recognizes ...
Breaking Biology News(10 mins):MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2Alere Inc. Announces Fourth Quarter 2014 Results 2Alere Inc. Announces Fourth Quarter 2014 Results 3Alere Inc. Announces Fourth Quarter 2014 Results 4Alere Inc. Announces Fourth Quarter 2014 Results 5Alere Inc. Announces Fourth Quarter 2014 Results 6Alere Inc. Announces Fourth Quarter 2014 Results 7Alere Inc. Announces Fourth Quarter 2014 Results 8Alere Inc. Announces Fourth Quarter 2014 Results 9Alere Inc. Announces Fourth Quarter 2014 Results 10Alere Inc. Announces Fourth Quarter 2014 Results 11Alere Inc. Announces Fourth Quarter 2014 Results 12Alere Inc. Announces Fourth Quarter 2014 Results 13Alere Inc. Announces Fourth Quarter 2014 Results 14Alere Inc. Announces Fourth Quarter 2014 Results 15Alere Inc. Announces Fourth Quarter 2014 Results 16Alere Inc. Announces Fourth Quarter 2014 Results 17Alere Inc. Announces Fourth Quarter 2014 Results 18Alere Inc. Announces Fourth Quarter 2014 Results 19Alere Inc. Announces Fourth Quarter 2014 Results 20Alere Inc. Announces Fourth Quarter 2014 Results 21Alere Inc. Announces Fourth Quarter 2014 Results 22Alere Inc. Announces Fourth Quarter 2014 Results 23Alere Inc. Announces Fourth Quarter 2014 Results 24Alere Inc. Announces Fourth Quarter 2014 Results 25Alere Inc. Announces Fourth Quarter 2014 Results 26Alere Inc. Announces Fourth Quarter 2014 Results 27Alere Inc. Announces Fourth Quarter 2014 Results 28Alere Inc. Announces Fourth Quarter 2014 Results 29Alere Inc. Announces Fourth Quarter 2014 Results 30Alere Inc. Announces Fourth Quarter 2014 Results 31Alere Inc. Announces Fourth Quarter 2014 Results 32Alere Inc. Announces Fourth Quarter 2014 Results 33Alere Inc. Announces Fourth Quarter 2014 Results 34Alere Inc. Announces Fourth Quarter 2014 Results 35
... known for a long time that some creatures evolve more ... plants. But it may be that height plays a role, ... S. National Evolutionary Synthesis Center. In a study ... Communications , Lanfear and colleagues report that shorter plants have ...
... at USC have found that a class of pharmaceuticals can ... The drugs, known as "TSPO ligands," are currently used for ... of TSPO ligand in young adult mice when pathology was ... was quite severe," said lead researcher Christian Pike of the ...
... Researchers at the University of Illinois at Chicago College of Medicine ... fat -- its main energy source -- and how changes in ... $2 million, 4-year grant from the National Heart, Lung and Blood ... for energy. These changes may play a major role in the ...
Cached Biology News:Small but speedy: Short plants live in the evolutionary fast lane 2Drugs found to both prevent and treat Alzheimer's disease in mice 2Do men's and women's hearts burn fuel differently? 2
(Date:2/27/2015)... , Feb. 27, 2015 A paper ... NCATS rare-diseases portfolio " in Science Translational ... financing technique to reduce the risk associated with ... potentially unlock new levels of funding for developing ... of a unique collaboration between scientists at the ...
(Date:2/27/2015)... 27, 2015 Immunovaccine Inc. (“Immunovaccine”) ... company, today announced that the U.S. Food and ... Track designation and Phase I clinical trials of ... the mutual co-development agreement signed with Gilead Life ... designation for the DPX-Survivac. , “We have been ...
(Date:2/27/2015)... , Feb. 27, 2015 Bionomics Limited (ASX:BNO, ... DisrupTOR-1 trial of BNC105 in patients with metastatic renal ... Orlando, Florida . The data will be ... City of Hope Comprehensive Cancer Center in ... The new data identifies Ferritin and IL-8 as ...
(Date:2/27/2015)... Illinois (PRWEB) February 27, 2015 FamilyFarms ... Sims, General Manager of State Line Farms, received the ... recognizes a producer, under the age of 35, who ... "It is an honor to win the Tomorrow's Top ... discovering who won the Top Producer Award and learning ...
Breaking Biology Technology:New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 2New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 3New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 4Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3New BNC105 Biomarker Data to be Presented at US Cancer Conference 2New BNC105 Biomarker Data to be Presented at US Cancer Conference 3New BNC105 Biomarker Data to be Presented at US Cancer Conference 4New BNC105 Biomarker Data to be Presented at US Cancer Conference 5Matt Sims Receives the 2015 Tomorrow’s Top Producer Horizon Award 2
... Leaders ... www.BioConferenceLive.com , ... MA (PRWEB) -- PlatformQ , the leading producer of online events for the healthcare, ... scientific community, today announced that G. Steven Burrill, Chief Executive Officer of Burrill & Company, ...
... , VIENNA, Sept. 30 Intarcia Therapeutics, Inc. today ... of ITCA 650 (DUROS® continuous delivery of exenatide) for ... Conference of the European Association for the Study of ... substantial reductions in fasting plasma glucose (FPG) within 24 ...
... BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) today announced that ... conference call and webcast on Wednesday, October 28, at 5:00 ... , U.S. / Canada Dial-in Number: ... Participant Code: 51404008, Replay Dial-in ...
Cached Biology Technology:CEO of Burrill & Company to Speak at BioConference Live Slated for November 17th and 18th 2CEO of Burrill & Company to Speak at BioConference Live Slated for November 17th and 18th 3Intarcia Therapeutics, Inc. Presents Positive Results of ITCA 650 Phase 1b Study in Type 2 Diabetes at the European Association for the Study of Diabetes Conference 2Intarcia Therapeutics, Inc. Presents Positive Results of ITCA 650 Phase 1b Study in Type 2 Diabetes at the European Association for the Study of Diabetes Conference 3Intarcia Therapeutics, Inc. Presents Positive Results of ITCA 650 Phase 1b Study in Type 2 Diabetes at the European Association for the Study of Diabetes Conference 4Intarcia Therapeutics, Inc. Presents Positive Results of ITCA 650 Phase 1b Study in Type 2 Diabetes at the European Association for the Study of Diabetes Conference 5BioMarin to Host Third Quarter 2009 Financial Results Conference Call and Webcast on Wednesday, October 28 at 5:00 p.m. ET 2
... Lone Wolf valve has the highest performance ... available on the market. This VSO valve ... and ensures maximum accuracy., Achieves rapid, ... and patient comfort. , Maintains ideal flow ...
Normal Hamster Serum...
...
Hamster Serum; U.S. sourced, ideal for those who seek an uncompromising quality. Low Hemoglobin levels; U.S. sourced, ideal for those who seek an uncompromising quality. Low Hemoglobin levels....
Biology Products: